Abiopharma

🔍 Sousa Gregory (Executive)

Company: Orange County Bancorp, Inc. /DE/ (OBT)

Report Date: 2026-03-19

Detailed Transactions and Holdings:

• Acquired 5,056 shares of Common Stock (Direct)
  Date: 2026-03-19 | Code: A | equity_swap_involved: 0 | shares_owned_after: 14,926.00 | transaction_form_type: 4 | Footnotes: F3, F1
• Sold 1,307 shares of Common Stock at $31.15 per share (Direct)
  Date: 2026-03-19 | Code: F | equity_swap_involved: 0 | shares_owned_after: 13,619.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-19 | Code: H | nature_of_ownership: By 401(k) | shares_owned_after: 7,065.00 | Footnotes: F4
• Holds 4,943 shares of Phantom Stock (Derivative)
  Date: 2026-03-19 | Code: H | shares_owned_after: 4,943.00 | Footnotes: F5, F5, F5

Footnotes:

• F1: Includes restricted stock units which vest at a rate of 1/3 per year commencing on March 21, 2025.
• F2: Includes restricted stock units which vest at a rate of 1/3 per year commencing on March 20, 2026.
• F3: Restricted stock units which vest at a rate of 1/3 per year commencing on March 19, 2027.
• F4: Reflects transactions not required to be reported pursuant to Section 16 of the Securities Exchange Act of 1934, as amended.
• F5: Represents deemed investments in connection with the Performance-Based SERP. Phantom stock interests under the Performance-Based SERP may be settled in shares of Company stock upon distribution to the reporting person, based on their prior election.